BioSpace News Archive

Aptevo Therapeutics Inc. announced that it will present two new posters at the Society for Immunotherapy of Cancer’s 35th Virtual Annual Meeting, to be held from Monday, November 9, 2020 to Saturday, November 14, 2020.

November 9, 2020 Rafarma Pharmaceuticals, Inc. OTC: shares the following letter to shareholders from Chairman Ilya Shpurov

Cannabics Pharmaceuticals Inc., a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced that it has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol.

Anticipates response on pre-investigational new drug (PIND) guidance from the FDA in November 2020 to proceed with Clinical Development Program for Mino-Wrap

Clinical Responses and Longer Progression-Free Survival in Patients with Wnt Signaling Alterations and High Tumoral DKK1 Expression

At this year’s American College of Rheumatology virtual meeting, Hospital for Special Surgery presented exciting research related to rheumatology and orthopedic surgery.

The campaign targets communities most at risk for low screening rates, including Black and Hispanic populations, and those with high risk factors.

WCG, the leading provider of services and solutions that improve and accelerate the conduct of clinical trials, announced that the U.S. Department of Veterans Affairs’ (VA) Office of Research and Development (ORD) is successfully implementing WCG’s IRBNet electronic submission and review system for more than 100 VA medical centers (VAMCs) that have research programs.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced that Inspire therapy will be integrated into the German hospital reimbursement system (“G-DRG”), effective January 1, 2021

Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months ended September 30, 2020.